mRNA·LNP Platform Technology
🧬 mRNA Platform Stability Simulator
Comparison of RNase resistance: SML's Circular Poly A vs. Conventional Linear Poly A
An innovative mRNA overcoming conventional mRNA limitations
Higher expression levels
Achieves higher expression rates both in vitro and in vivo, enabling greater protein production with lower mRNA quantities.
Enhanced stability
Improved in vivo stability prolongs mRNA persistence in the body, partially addressing its inherent rapid degradation.
Optimized delivery
Proprietary LNP formulation ensures efficient intracellular delivery, maximizing therapeutic efficacy across diverse applications.
SML Biopharm possesses an mRNA platform with optimized UTR and poly(A) tail designed to enhance stability and expression efficiency. While advancing our next-generation mRNA platform and drug pipeline, we independently develop lipid nanoparticles (LNP) for efficient delivery, driving effective R&D and rapid research progress.
Pipeline
Developing innovative therapeutics for various diseases based on mRNA platform technology.
Cancer Vaccine
Immune Response Based Therapeutics
Optimization
Cancer Vaccine / mRNA-based bsAb
Immune Response Based Therapeutics
Optimization
Prophylactic Vaccine
Immune Response Based Therapeutics
Optimization
Antibody
In-vivo Protein Expression Therapeutics
Optimization
mRNA-based Protein (Novel Target)
In-vivo Protein Expression Therapeutics
Optimization
mRNA-based bsAb
In-vivo Protein Expression Therapeutics
Optimization
Development Process
SML Biopharm's drug development process
Discovery
Target discovery and
candidate exploration
Preclinical
Preclinical testing and
efficacy/safety validation
Clinical Trial
Clinical trials
(Phase 1-3)
Regulatory
Regulatory submission
and approval
Commercialization
Commercialization and
market launch
Publications
SML Biopharm's publication portfolio
No publication data available.